Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases
Digital Health Global
MARCH 16, 2023
The seed round was co-led by Wellington Partners and Forbion and includes non-dilutive financing from BMBF GO-Bio, a prestigious German government initiative aimed at supporting the most innovative startups in the life sciences. Forbion invests in life sciences companies that are active in the (bio) pharmaceutical space.
Let's personalize your content